Phase 3 Readout
SVRA: Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb
May 30, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- May 30, 2027
- Company
- Savara Inc (SVRA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Neb
- Company
- Savara Inc (SVRA)
- Indication
- Autoimmune Pulmonary Alveolar Proteinosis